Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411267 · ClinicalTrials.gov registry record · Phase 1
AC220 for Children With Relapsed/Refractory ALL or AML
A Phase 1 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01411267 is a Phase 1 study that has completed, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 24 participants.
The verdict
NCT01411267, a Phase 1 study, has completed, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Methotrexate
- DRUG AC220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-09-01 |
| Est. Completion | 2013-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411267
The ClinicalTrials.gov registry entry for NCT01411267 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Etoposide is the first listed.
NCT01411267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411267 about?
NCT01411267 is a clinical study titled "AC220 for Children With Relapsed/Refractory ALL or AML". This is a phase I study of the investigational drug AC220 combined with cytarabine and etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).
What is the current status of trial NCT01411267?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-09-01. Estimated completion is 2013-09-12.
What interventions are being tested in trial NCT01411267?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Methotrexate (DRUG), AC220 (DRUG).
Who is sponsoring clinical trial NCT01411267?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.